Safety and efficacy analysis of ibrutinib in 32 patients with CLL and various B-cell lymphomas: real-world data from a single-center study in Turkey

BACKGROUND: Ibrutinib is an oral irreversible Bruton’s tyrosine kinase inhibitor. Here, we demonstrate the efficacy and safety of ibrutinib using real-life data from patients with marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), Waldenström macroglobulinemia (WM), and follicular...

Descripción completa

Detalles Bibliográficos
Autores principales: Göçer, Mesut, Kurtoğlu, Erdal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784134/
https://www.ncbi.nlm.nih.gov/pubmed/33303706
http://dx.doi.org/10.5045/br.2020.2020158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784134/
https://www.ncbi.nlm.nih.gov/pubmed/33303706
http://dx.doi.org/10.5045/br.2020.2020158

Ejemplares similares